A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered SRSD107 in Healthy Participants
Latest Information Update: 23 May 2025
At a glance
- Drugs SRSD 107 (Primary)
- Indications Thromboembolism; Thrombosis
- Focus Adverse reactions; First in man
- Sponsors Sirius Therapeutics
Most Recent Events
- 19 May 2025 According to a CRISPR Therapeutics media release, results from this study were presented at the 2025 Annual Scientific Sessions of the American College of Cardiology.
- 18 May 2025 Status changed from active, no longer recruiting to completed.
- 19 Dec 2024 Planned End Date changed from 1 Jan 2025 to 1 Jun 2025.